-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Jaktinib Hydrochloride in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Rheumatoid Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Jaktinib Hydrochloride in Rheumatoid Arthritis Drug Details: Jaktinib is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Donafenib Tosylate in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Donafenib Tosylate in Head And...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Metastatic Melanoma Drug Details: Niraparib (MK-4827, Zejula) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Metastatic Adenocarcinoma of The Pancreas Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Donafenib Tosylate in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Donafenib Tosylate in Pancreatic Cancer Drug Details: Donafenib tosylate (Zepsun) is a deuterated sorafenib derivative....
-
Product Insights
NewNeuroendocrine Tumors – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Tumors – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms include hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy, and...
-
Product Insights
NewPapillary Thyroid Cancer – Drugs In Development, 2024
Empower your strategies with our Papillary Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 75% to 85% of all cases. It affects more women than men and can occur at any age, but especially between 30 and 50 years old. PTC is usually slow-growing and well-differentiated, meaning it resembles normal thyroid cells. However, it can also spread to the lymph nodes...
-
Product Insights
NewChronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2024
Empower your strategies with our Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2024 report and make more profitable business decisions. Primary myelofibrosis (PMF) is a rare bone marrow disorder marked by irregularities in blood cell production and the development of fibrous tissue within the bone marrow. Hematopoietic stem cells in the bone marrow, responsible for generating red blood cells, white blood cells, and platelets, undergo DNA changes in PMF, leading to continuous abnormal cell reproduction. Over time, these aberrant...
-
Product Insights
NewFollicular Thyroid Cancer – Drugs In Development, 2024
Empower your strategies with our Follicular Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Follicular thyroid carcinoma is a cancer that forms in follicular cells of the thyroid. Follicular thyroid cancer constitutes 10 to 15% of all thyroid cancer cases, making it the second most common. Unlike differentiated types, undifferentiated types are rare. Diagnosis of follicular thyroid carcinoma relies on pathologic confirmation of follicular cells devoid of the nuclear atypia seen in papillary thyroid cancer,...
-
Product Insights
NewNeuroendocrine Carcinoma – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine carcinoma (NEC) is a rare type of cancer that arises from neuroendocrine cells, which are cells that have both nerve and hormone functions. NEC can occur in various organs, such as the lungs, pancreas, stomach, intestines, appendix, rectum, breast, kidney, ovaries, or testicles. NEC can be classified into well-differentiated or poorly differentiated tumors, depending on how they look under the microscope...